CANCER GENETICS, INC. (NASDAQ:CGIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 18, 2019, the Board of Directors (the “Board”) of Cancer Genetics, Inc. (the “Company”) accepted Dr. Michael J. Welsh’s resignation from his role as director and his membership on the compensation committee and his membership on the nominating committee of the Board. The resignation was not due to any disagreement on any matter relating to the Company’s operations, policies or practices.
On July 8, 2019, the Board received a letter from John Pappajohn to which he resigned as a director of the Board, effective immediately.
According to his resignation letter, and based on information known to the Company, Mr. Pappajohn’s decision to resign was due to his disagreement with the Company’s management regarding the Company’s entering into the Secured Creditor Asset Purchase Agreement, by and among the Company, Gentris, LLC, a wholly owned subsidiary of the Company, Partners for Growth IV, L.P., Interpace Diagnostics Group, Inc. and a newly-formed subsidiary of IDXG, Interpace BioPharma, Inc. and the transactions contemplated thereby. A copy of Mr. Pappajohn’s letter of resignation is attached hereto as Exhibit 17.1.
The Company has provided Mr. Pappajohn with a copy of the disclosures in this Form 8-K and the opportunity to furnish the Company with a letter addressed to the Company stating whether he agrees with the statements made by the Company in response to this Item 5.02 and if not, stating the respects in which he does not agree. Upon the receipt of any such letter from Mr. Pappajohn, the Company will file any such letter as an exhibit to an amendment to this Form 8-K, no later than two business days after it is received.
Item 9.01. Financial Statements and Exhibits.
|17.1||Director resignation letter, dated July 8, 2019|
CANCER GENETICS, INC Exhibit
EX-17.1 2 ex17-1.htm Exhibit 17.1 From: John Pappajohn Sent: Monday,…
To view the full exhibit click
About CANCER GENETICS, INC. (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.